Concomitant administration of isradipine and spirapril prevents reduction of renal function induced by acute administration of spirapril in patients with reduced renal function.
Angiotensin-converting enzyme (ACE) inhibitors may cause a further decrease in renal function in patients who already have renal failure. The acute effects of the ACE inhibitor spirapril on renal function were investigated in 10 patients with mild-to-moderate renal failure (serum creatinine of 1.5-2.5 mg/dl). Acute oral administration of spirapril at 6 mg resulted in decreases in inulin clearance (from 53.7 +/- 12.8 to 44.6 +/- 8.8 ml/min; p < 0.02; n = 5) and in PAH clearances (from 215 +/- 141.9 to 184 +/- 37.8 ml/min; p < 0.006; n = 5). However, when the acute administration of 6 mg of spirapril was given concomitantly with isradipine at 5 mg, there were no changes in these renal function parameters.
Wittenberg
C
C
Institute of Hypertension and Nephrology, Beilinson Medical Center, Petah-Tiqva, Israel.
Erman
A
A
Shohat
J
J
Boner
G
G
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D004338:Drug Combinations; D004656:Enalapril / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D017275:Isradipine / Q000627:therapeutic use*; D007668:Kidney / Q000187:drug effects* / Q000503:physiopathology; D007676:Kidney Failure, Chronic / Q000188:drug therapy*; D013997:Time Factors
D000806:Angiotensin-Converting Enzyme Inhibitors; D004338:Drug Combinations; D004656:Enalapril; C052555:spirapril; D017275:Isradipine